SRI-37330
目录号 : GC68451SRI-37330是硫氧还蛋白相互作用蛋白（TXNIP）的小分子抑制剂。
Cas No.:2322245-42-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SRI-37330 is a small molecule inhibitor of thioredoxin interacting protein (TXNIP) [1]. SRI-37330 helps protect β cells and increase their number by reducing TXNIP levels, thereby improving insulin secretion capacity [2-3]. SRI-37330 is mainly used to treat diabetes [4].
In adult murine ventricular cardiomyocytes (AMVCs), SRI-37330 (0-5μM; 24h) dose-dependently inhibited the expression of cleaved-Casp1 and TXNIP/NLRP3 in Doxorubicin-treated AMVCs [5]. In FTOoe A549 cells, SRI-37330 (10μM; 24h) significantly reduced the expression of TXNIP protein in cells and abolished the increase in the expression of pyroptosis-related proteins [6]. In rat INS-1 cells, SRI-37330 can significantly inhibit the expression of TXNIP [7].
In diabetic mice model, basal glucose production in the liver of mice treated with SRI-37330 (100mg/kg; po; 3 weeks) was significantly downregulated [7]. In high fat diet mice model, oral SRI-37330 (100mg/kg; po; 4 weeks) treatment protects against high-fat diet-induced glucose intolerance [8].
References:
[1]. Choi EH, Park SJ. TXNIP: A key protein in the cellular stress response pathway and a potential therapeutic target. Experimental & molecular medicine. 2023 Jul; 55(7): 1348-1356.
[2]. Datta S, Rahman MA, Koka S, et al. Mitigation of nicotine-induced podocyte injury through inhibition of thioredoxin interacting protein. Biomedicine & Pharmacotherapy. 2025 Jun 1; 187: 118110.
[3]. Dalle S, Abderrahmani A, Renard E. Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes. Frontiers in endocrinology. 2023 Mar 15; 14: 1076343.
[4]. Demir S, Nawroth PP, Herzig S, et al. Emerging targets in type 2 diabetes and diabetic complications. Advanced Science. 2021 Sep; 8(18): 2100275.
[5]. Ma Y, Wang Y, Chen R, et al. Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk. Signal Transduction and Targeted Therapy. 2025 May 14;10(1):1-26.
[6]. Xie WM, Su W, Liu XY, et al. FTO deficiency alleviates LPS-induced acute lung injury by TXNIP/NLRP3-mediated alveolar epithelial cell pyroptosis. American Journal of Respiratory Cell and Molecular Biology. 2024 May; 70(5): 351-363.
[7]. Thielen LA, Chen J, Jing G, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metabolism. 2020 Sep 1; 32(3): 353-365.
[8]. Jo S, Jing G, Chen J, et al. Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism. 2025 Apr; 27(4): 2223-2231.
SRI-37330是硫氧还蛋白相互作用蛋白（TXNIP）的小分子抑制剂 [1]。SRI-37330通过降低TXNIP水平来保护β细胞并增加其数量，从而提高胰岛素分泌能力 [2-3]。SRI-37330主要用于治疗糖尿病 [4]。
在成年小鼠心室肌细胞（AMVC）中，SRI-37330（0-5μM；24h）剂量依赖性地抑制了经Doxorubicin处理的AMVC中cleaved-Casp1和TXNIP/NLRP3的表达 [5]。在 FTOoe A549细胞中，SRI-37330（10μM；24h）显著降低了细胞中TXNIP蛋白的表达，并消除了细胞焦亡相关蛋白表达的增加 [6]。在大鼠INS-1细胞中，SRI-37330可显著抑制TXNIP的表达 [7]。
在糖尿病小鼠模型中，经SRI-37330（100mg/kg；po；3周）治疗的小鼠肝脏基础葡萄糖生成显著下调 [7]。在高脂饮食小鼠模型中，口服SRI-37330（100mg/kg；po；4周）治疗可预防高脂饮食引起的葡萄糖不耐受 [8]。
| Cell experiment [1]: | |
Cell lines | Adult murine ventricular cardiomyocytes (AMVCs) |
Preparation Method | AMVCs were isolated and cocultured with 4T1 breast cancer cells in a Transwell system. The cells were treated with Doxorubicin (1μM) for 24h, followed by treatment with varying concentrations of VX765 (0–100nM), MCC950 (0–50nM), or SRI-37330 (0–5μM). |
Reaction Conditions | 0-5μM; 24h |
Applications | SRI-37330 dose-dependently inhibited the expression of cleaved-Casp1 and TXNIP/NLRP3 in Doxorubicin-treated AMVCs. |
| Animal experiment [2]: | |
Animal models | High fat diet (HFD) mice model |
Preparation Method | Mice on HFD mice were randomly assigned to experimental groups to be treated with oral SRI-37330 (100mg/kg in the drinking water) (n = 12) or (n = 3) or without SRI-37330 (n = 20) or (n = 4). Other treatments were as previously reported, metformin (250mg/kg), or empagliflozin (10mg/kg) in the drinking water, and leptin (7.2mg/kg i.p.). |
Dosage form | 100mg/kg; po; 4 weeks |
Applications | Oral SRI-37330 treatment protects against high-fat diet-induced glucose intolerance. |
References: | |
| Cas No. | 2322245-42-9 | SDF | Download SDF |
| 分子式 | C16H19F3N4O2S | 分子量 | 388.41 |
| 溶解度 | DMSO : 100 mg/mL (257.46 mM; Need ultrasonic) | 储存条件 | Store at -20°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5746 mL | 12.873 mL | 25.746 mL |
| 5 mM | 514.9 μL | 2.5746 mL | 5.1492 mL |
| 10 mM | 257.5 μL | 1.2873 mL | 2.5746 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet